Key facts
- Lyte’s last known valuation is $482.0M (Jan 2026).
- It has raised $107.0M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($60.0M) in Jan 2026.
- Notable investors include Fidelity Management & Research Company, Atreides Management, EXOR Seeds, Key1 Capital, Avigdor Willenz — 6 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Lyte
Funding rounds
1 roundsAbout Lyte
Developer of an AI-powered interoperability and workflow orchestration platform designed to unify payer, provider, and third-party data in real time for healthcare revenue cycle and patient access use cases. The company's platform leverages FHIR-native architecture, scalable microservices, API-first connectivity, reusable integration patterns, event-driven orchestration, low-latency data processing, configurable rules engines, and embedded AI models for automation and decision support, enabling healthcare organizations and technology vendors to rapidly deploy connected applications, reduce technical debt, improve data liquidity, and achieve more accurate, timely, and efficient operational outcomes.
- Industry
- Other Hardware
- Sector
- Information Technology
- HQ
- Mountain View, CA, United States
- Founded
- 2021
- Website
- lyte.ai/
- Ownership
- Privately Held (backing)
Lyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lyte in its N-PORT filings yet. We sweep new filings monthly.